Social media promoters claim peptides speed healing, smooth skin and extend life, and CBS notes the HHS Secretary counts himself a fan.
Recap by typeshit. Post by CBS Mornings on X.
CNBC's investing team lifts its target on Lilly shares and argues the obesity drug run still has room to grow.
The Pharma Letter looks at how semaglutide generics are changing strategy in India, with Torrent eyeing an expansion into Brazil.
Semafor looks at how little national political figures have said about what the new class of weight loss drugs means for policy.
The doctors take on two of the topics their followers ask about most, giving their verdict on statins and Ozempic.
Lilly's 80-week trial in 1,298 adults with type 2 diabetes also showed bigger A1C drops. Dropout from side effects reached 7.9% on the higher dose versus 2.7% on Ozempic.
Bikman points to the drop in liver fat among people with fatty liver as the part of Lilly's retatrutide results that interests him most.
Loading…